DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Peeters M. et al.
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Clin Cancer Res 2015;
21: 5469-5479
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.